Nonthyroidal illnesses syndrome in full-term newborns with sepsis
Carregando...
Citações na Scopus
9
Tipo de produção
article
Data de publicação
2015
Título da Revista
ISSN da Revista
Título do Volume
Editora
Sociedade Brasileira de Endocrinologia e Metabologia
Citação
ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, v.59, n.6, p.528-534, 2015
Resumo
ABSTRACT Objective To assess hormonal changes in nonthyroidal illness syndrome (NTIS) in full-term newborns (NT) with sepsis. Materials and methods We included 28 NT with sepsis divided into 2 groups according to the time of normalization of serum and clinical indicators of infection: group A(A), 16 NT with improvement in up to 8 days; and group B(B), 12 NT improvement after 8 days. Among the 28 NT, 15 NT progressed to septic shock, with 5 NT group A and 10 NT in group B. NT were excluded when they showed severe sepsis and asphyxia, and congenital malformations, as well as those whose mothers had thyroid disease and IUGR. Results 17 NT (60.7%) presented NTIS. Low T3 was observed in NTIS in 10 NT (58.8%), and low T4 and T3 in 5 NT (29.5%), all of them with septic shock. Two NT showed mixed changes (11.7%). After sepsis was cured, there was no hormonal change, except in 3 NT. Administration of dopamine, furosemide, and corticosteroids did not affect the results. Conclusions This study indicates that nonthyroidal illness syndrome may be transiently present during sepsis in full-term newborns, especially in cases of prolonged sepsis. Low T3 can occur without changes in reverse T3 (different from adults), and low T4 and T3 occur mainly in patients with septic shock. Arch Endocrinol Metab. 2015;59(6):528-34
Palavras-chave
Full-term newborn, thyroidal hormone, sepsis, septic shock
Referências
- Reisner BS, 1999, J CLIN MICROBIOL, V37, P2024
- Ehl S, 1997, PEDIATRICS, V99, P216, DOI 10.1542/peds.99.2.216
- Lacour AG, 2001, EUR J PEDIATR, V160, P95, DOI 10.1007/s004310000681
- Stockigt JR, 1996, CLIN CHEM, V42, P188
- CHOPRA IJ, 1975, J CLIN ENDOCR METAB, V41, P911
- VANDENBERGHE G, 1994, CRIT CARE MED, V22, P1747
- Peeters RP, 2005, J CLIN ENDOCR METAB, V90, P4559, DOI 10.1210/jc.2005-0535
- Goldsmit GS, 2011, J PERINAT MED, V39, P59, DOI 10.1515/JPM.2010.120
- Dellinger RP, 2013, CRIT CARE MED, V41, P580, DOI 10.1097/CCM.0b013e31827e83af
- Golombek SG, 2008, SEMIN PERINATOL, V32, P413, DOI 10.1053/j.semperi.2008.09.010
- MUNRO SL, 1989, J CLIN ENDOCR METAB, V68, P1141
- Economidou F, 2011, HORM-INT J ENDOCRINO, V10, P117
- Dilli D, 2012, J CLIN RES PEDIATR E, V4, P66, DOI 10.4274/jcrpe.625
- FRANKLIN R, 1985, J PEDIATR-US, V106, P124, DOI 10.1016/S0022-3476(85)80481-9
- FRANKLIN R, 1985, J PEDIATR-US, V107, P599, DOI 10.1016/S0022-3476(85)80031-7
- Goldstein Brahm, 2005, Pediatr Crit Care Med, V6, P2, DOI 10.1097/01.PCC.0000149131.72248.E6
- Graf Hans, 2002, Arq Bras Endocrinol Metab, V46, P51, DOI 10.1590/S0004-27302002000100008
- GROSS I, 1984, PEDIATR RES, V18, P191
- Hulst JM, 2006, CLIN NUTR, V25, P154, DOI 10.1016/j.clnu.2005.10.006
- KAPTEIN EM, 1980, J CLIN ENDOCR METAB, V51, P387
- Langton JE, 2002, ENDOCRIN METAB CLIN, V31, P159, DOI 10.1016/S0889-8529(01)00008-1
- LIM CF, 1988, J CLIN ENDOCR METAB, V67, P682
- Nagaya T, 2000, J CLIN INVEST, V106, P393, DOI 10.1172/JCI7771
- SQUIRE EN, 1982, PEDIATR INFECT DIS J, V1, P85, DOI 10.1097/00006454-198203000-00004
- WILSON DM, 1982, J PEDIATR-US, V101, P113, DOI 10.1016/S0022-3476(82)80198-4
- Yildizdas D, 2004, J PEDIATR ENDOCR MET, V17, P1435
- 2005, J Clin Endocrinol Metab, V90, P5613
- 2002, Indian J Pediatr, V69, P663
- 2005, Intensive Care Med, V31, P970
- 2000, Rev Endocr Metab Disord, V1, P43
- 2014, Front Endocrinol, V5
- 2009, Endocrine, V36, P355
- 1983, Ann Intern Med, V98, P946
- Moura Egberto G. de, 2004, Arq Bras Endocrinol Metab, V48, P40, DOI 10.1590/S0004-27302004000100006